lilly tirzepatide weight loss Lilly's Zepbound tops Wegovy for in head-to-head trial Tirzepatide weight-loss study shows promising

Patients with atrial arrhythmias had risk factors for occurrence and continuation of arrhythmias: they were significantly older, more often had obesity, a history of AF and LV hypertrophy and were current tobacco users

Extensive preclinical research shows it influences collagen synthesis, antioxidant defense, and tissue regeneration in cell and animal models

Give your body time before increasing the dose If your symptoms are intense, your clinician may pause your dose increase to help your gut settle

SIRT6 protects vascular smooth muscle cells from osteogenic transdifferentiation via Runx2 in chronic kidney disease

doi: 10.1053/j.gastro.2012.05.008 200 AsarianLGearyN